Gena Wang
Stock Analyst at Barclays
(2.41)
# 2,424
Out of 5,182 analysts
238
Total ratings
43.4%
Success rate
-0.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gena Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Maintains: Overweight | $87 → $95 | $66.35 | +43.18% | 7 | Apr 6, 2026 | |
| LEGN Legend Biotech | Maintains: Overweight | $90 → $80 | $18.69 | +328.04% | 8 | Feb 4, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $81 → $50 | $24.57 | +103.50% | 7 | Nov 24, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Overweight | $38 → $33 | $9.66 | +241.61% | 3 | Nov 11, 2025 | |
| MRNA Moderna | Maintains: Equal-Weight | $31 → $25 | $52.84 | -52.69% | 11 | Nov 7, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $24 → $14 | $14.78 | -5.28% | 9 | Nov 7, 2025 | |
| SGMO Sangamo Therapeutics | Downgrades: Equal-Weight | $5 → $1 | $0.26 | +290.93% | 5 | Nov 7, 2025 | |
| PTCT PTC Therapeutics | Maintains: Equal-Weight | $46 → $68 | $73.01 | -6.86% | 17 | Nov 6, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Equal-Weight | $22 → $20 | $22.15 | -9.71% | 16 | Nov 5, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Equal-Weight | $408 → $414 | $444.28 | -6.82% | 18 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $9 | $8.23 | +9.36% | 8 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $9 | $9.67 | -6.93% | 11 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $460 → $527 | $339.41 | +55.27% | 9 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $95 | $76.76 | +23.76% | 14 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $80 | $55.47 | +44.22% | 16 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $8 | $4.16 | +92.31% | 5 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $7 → $17 | $45.07 | -62.28% | 10 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $37 | $9.30 | +297.85% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $42 → $56 | $56.86 | -1.51% | 17 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $25 → $21 | $30.30 | -30.69% | 10 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $31 | $10.05 | +208.46% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $3.39 | -11.50% | 9 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $9 | $26.98 | -66.64% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $25 | $8.68 | +188.02% | 5 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $18 | $11.29 | +59.43% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $9 | $7.57 | +18.89% | 6 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $275 | $5.19 | +5,198.65% | 1 | Jan 6, 2017 |
Cytokinetics
Apr 6, 2026
Maintains: Overweight
Price Target: $87 → $95
Current: $66.35
Upside: +43.18%
Legend Biotech
Feb 4, 2026
Maintains: Overweight
Price Target: $90 → $80
Current: $18.69
Upside: +328.04%
Ultragenyx Pharmaceutical
Nov 24, 2025
Maintains: Overweight
Price Target: $81 → $50
Current: $24.57
Upside: +103.50%
4D Molecular Therapeutics
Nov 11, 2025
Maintains: Overweight
Price Target: $38 → $33
Current: $9.66
Upside: +241.61%
Moderna
Nov 7, 2025
Maintains: Equal-Weight
Price Target: $31 → $25
Current: $52.84
Upside: -52.69%
Intellia Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $24 → $14
Current: $14.78
Upside: -5.28%
Sangamo Therapeutics
Nov 7, 2025
Downgrades: Equal-Weight
Price Target: $5 → $1
Current: $0.26
Upside: +290.93%
PTC Therapeutics
Nov 6, 2025
Maintains: Equal-Weight
Price Target: $46 → $68
Current: $73.01
Upside: -6.86%
Sarepta Therapeutics
Nov 5, 2025
Maintains: Equal-Weight
Price Target: $22 → $20
Current: $22.15
Upside: -9.71%
Vertex Pharmaceuticals
Nov 4, 2025
Maintains: Equal-Weight
Price Target: $408 → $414
Current: $444.28
Upside: -6.82%
Nov 4, 2025
Maintains: Overweight
Price Target: $10 → $9
Current: $8.23
Upside: +9.36%
Nov 4, 2025
Maintains: Equal-Weight
Price Target: $11 → $9
Current: $9.67
Upside: -6.93%
Oct 31, 2025
Maintains: Overweight
Price Target: $460 → $527
Current: $339.41
Upside: +55.27%
Oct 30, 2025
Maintains: Overweight
Price Target: $80 → $95
Current: $76.76
Upside: +23.76%
Oct 28, 2025
Maintains: Overweight
Price Target: $86 → $80
Current: $55.47
Upside: +44.22%
Oct 17, 2025
Maintains: Overweight
Price Target: $4 → $8
Current: $4.16
Upside: +92.31%
Sep 25, 2025
Upgrades: Equal-Weight
Price Target: $7 → $17
Current: $45.07
Upside: -62.28%
Aug 8, 2025
Maintains: Overweight
Price Target: $50 → $37
Current: $9.30
Upside: +297.85%
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $42 → $56
Current: $56.86
Upside: -1.51%
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $25 → $21
Current: $30.30
Upside: -30.69%
Feb 28, 2025
Maintains: Overweight
Price Target: $26 → $31
Current: $10.05
Upside: +208.46%
Dec 13, 2024
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $3.39
Upside: -11.50%
Dec 22, 2022
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $26.98
Upside: -66.64%
Nov 2, 2022
Upgrades: Equal-Weight
Price Target: $16 → $25
Current: $8.68
Upside: +188.02%
May 13, 2022
Maintains: Overweight
Price Target: $32 → $18
Current: $11.29
Upside: +59.43%
Aug 9, 2019
Maintains: Underweight
Price Target: $21 → $9
Current: $7.57
Upside: +18.89%
Jan 6, 2017
Initiates: Buy
Price Target: $275
Current: $5.19
Upside: +5,198.65%